NCT05956639View on ClinicalTrials.gov

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC

PHASE3RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
DRUG

6-month course of antiandrogen drugs

6-month course of Rezvilutamide and ADT + chemotherapy

DRUG

Long-term course of antiandrogen drugs

Long-term course of Rezvilutamide and ADT + chemotherapy

Trial Locations (1)

210029

RECRUITING

Urology dpt, First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER